Metabolic Syndrome X  >>  Tekturna (aliskiren)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
ALTO, NCT00542269 / 2007-003677-10: Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome

Terminated
4
178
Europe
Amlodipine, Aliskiren, Ramipril
Novartis
Hypertension With Metabolic Syndrome
07/09
07/09
AIMS, NCT00797316: Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

Completed
4
532
US
Aliskiren, Hydrochlorothiazide
Novartis
Hypertension
12/09
12/09
TARGET, NCT01138423 / 2009-015982-29: Treatment of Adiposity Related hypErTension

Completed
4
32
Europe
Aliskiren, Brand name: Ralisez, ATC-code: C09XA02, Moxonidine, No brand name (generic product), ATC-code: C02AC05, Hydrochlorothiazide, ATC-code: C03AA03, Placebo (for aliskiren), Placebo (for moxonidine and hydrochlorothiazide)
UMC Utrecht, Novartis Pharmaceuticals
Hypertension, Abdominal Obesity, Metabolic Syndrome
02/12
02/12

Download Options